Lear (LEA) news
Recent news
Lear increases share repurchase authorization to $1.5B, extends authorization
AInvest Wire · Sep 24, 2026Tempest Therapeutics Inc: H.C. Wainwright cuts target price to $7 from $11
H.C. Wainwright & Co. has revised its price target for Tempest Therapeutics Inc (NASDAQ: TSTM), lowering it from $11 to $7, effective September 24, 2026[1]. The adjustment reflects the firm’s reassessment of the company’s near-term clinical and regulatory outlook. Despite the reduced target, the…
AInvest Wire · Sep 24, 2026Five sees FY net sales $5.63B to $5.71B, saw $5.40B to $5.48B
Lear Corporation (NYSE: LEA) reported Q2 2026 earnings on July 31, 2026, with earnings per share (EPS) of $4.28, surpassing the consensus estimate of $3.98 by $0.30. Quarterly revenue increased 3.0% year-over-year to $6.21 billion, exceeding the estimated $6.15 billion . The company’s trailing EPS…
AInvest Wire · Sep 2, 2026BNP Paribas cuts Lear Corp to neutral from outperform; cuts target price to $145 from $170
AInvest Wire · Aug 3, 2026JP Morgan raises target price to $175 from $159 for Lear Corp
AInvest Wire · Aug 3, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.